OLDSMAR, Fla., March 15, 2013 (GLOBE NEWSWIRE) -- A patent issued to Saneron CCEL Therapeutics, Inc. and the University of South Florida may facilitate increased use of cord blood stem cells in medical therapies, according to Linda Kelley, Ph.D., chief scientific officer with Cryo-Cell International (OTCQB:CCEL). Cryo-Cell is a major investor in Saneron CCEL Therapeutics, a Tampa, Fla.-based research firm with rights to 20 patents related to their cellular therapy technology.
Cryo-Cell International Affiliate Earns Patent For Processing Umbilical Cord Blood For Therapeutic Use In Treating Neurodegenerative Diseases And Spinal Cord And Brain Injuries
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts